Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial
- 2 May 2025
- journal article
- Published by Elsevier in The Lancet Rheumatology
- Vol. 7 (7) , e485-e494
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca plc
This publication has 27 references indexed in Scilit:
- LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trialsAnnals of the Rheumatic Diseases, 2025
- A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusArthritis & Rheumatology, 2022
- Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumabThe Lancet Rheumatology, 2022
- Trial of Anifrolumab in Active Systemic Lupus ErythematosusNew England Journal of Medicine, 2020
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialThe Lancet Rheumatology, 2019
- Systemic lupus erythematosusNature Reviews Disease Primers, 2016
- Burden of Systemic Lupus Erythematosus on Employment and Work Productivity: Data From a Large Cohort in the Southeastern United StatesArthritis Care & Research, 2013
- Interim Scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L Value SetsValue in Health, 2012
- Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6DQuality of Life Research, 2005
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990